LIPC-E97G Gain-of-function variant potentiates the hypocholesterolemic and anti-atherogenic effects of evinacumab in Ldlr-/- mice
Lucie Vince, Amélie Thouzeau, Audrey Ayer, Bertrand Cariou, Antoine Rimbert, Cédric Le May
This study shows that the LIPC-E97G variant enhances the cholesterol-lowering and anti-atherogenic effects of evinacumab in Ldlr-/- mice.
bioRxiv · Oct 2, 2026 · PreprintPhysiology